{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:12:19Z","timestamp":1785899539827,"version":"3.56.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009874","name":"Universit\u00e9 de Sherbrooke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009874","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.vaccine.2021.08.019","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T23:51:42Z","timestamp":1628639502000},"page":"7300-7307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Does BCG provide long-term protection against SARS-CoV-2 infection? A case\u2013control study in Quebec, Canada"],"prefix":"10.1016","volume":"39","author":[{"given":"Jacques","family":"P\u00e9pin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8936-3307","authenticated-orcid":false,"given":"Annie-Claude","family":"Labb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Carignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Elise","family":"Parent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6024-1282","authenticated-orcid":false,"given":"Jennifer","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2758-933X","authenticated-orcid":false,"given":"Cynthia","family":"Grenier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3524-1774","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Beauchemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"De Wals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8300-8416","authenticated-orcid":false,"given":"Louis","family":"Valiquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5215-8086","authenticated-orcid":false,"given":"Marie-Claude","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2021.08.019_b0005","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1473-3099(15)00400-4","article-title":"Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study","volume":"16","author":"Nguipdop-Djomo","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.08.019_b0010","unstructured":"World Health Organization. Report on BCG vaccine use for protection against mycobacterial infections including tuberculosis, leprosy, and other nontuberculous mycobacteria infections. https:\/\/www.who.int\/immunization\/sage\/meetings\/2017\/october\/1_BCG_report_revised_version_online.pdf. Accessed 10 May 2021."},{"issue":"12","key":"10.1016\/j.vaccine.2021.08.019_b0015","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.cmi.2019.04.020","article-title":"Non-specific effects of BCG vaccine on viral infections","volume":"25","author":"Moorlag","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.vaccine.2021.08.019_b0020","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","article-title":"Defining trained immunity and its role in health and disease","volume":"20","author":"Netea","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2021.08.019_b0025","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1080\/21645515.2019.1706930","article-title":"BCG: a vaccine with multiple faces","volume":"16","author":"Yamazaki-Nakashimada","year":"2020","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"10.1016\/j.vaccine.2021.08.019_b0030","doi-asserted-by":"crossref","first-page":"e1228","DOI":"10.1002\/cti2.1228","article-title":"Trained immunity as a novel approach against COVID-19 with a focus on Bacillus Calmette-Gu\u00e9rin vaccine: mechanisms, challenges and perspectives","volume":"9","author":"Sohrabi","year":"2020","journal-title":"Clin Transl Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2021.08.019_b0035","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1080\/21645515.2020.1818522","article-title":"BCG vaccine: a hope to control COVID-19 pandemic amid crisis","volume":"16","author":"Malik","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.08.019_b0040","unstructured":"Naeslund C. R\u00e9sultats des exp\u00e9riences de vaccination par le BCG poursuivies dans le Norrbotten (Su\u00e8de) (Septembre 1927-D\u00e9cembre 1931) [Results of BCG vaccination experiments conducted in Norrbotten (Sweden) (September 1927-December 1931)]. In: Vaccination pr\u00e9ventive de la tuberculose de l'homme et des animaux par le BCG. Rapports et documents provenant de divers pays (la France except\u00e9e) transmis \u00e0 l'Institut Pasteur en 1932 [BCG preventive vaccination against tuberculosis in humans and animals. Reports and documents from various countries (France excepted) transmitted to the Institut Pasteur in 1932]. Paris: Masson et Cie, 1932:274\u221281."},{"key":"10.1016\/j.vaccine.2021.08.019_b0045","first-page":"433","article-title":"Sur l'immunit\u00e9 para-sp\u00e9cifique conf\u00e9r\u00e9e par le BCG [About para-specific immunity conferred by BCG]","volume":"50","author":"Calmette","year":"1933","journal-title":"Ann Inst Pasteur"},{"key":"10.1016\/j.vaccine.2021.08.019_b0050","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1093\/cid\/civ144","article-title":"Nonspecific (heterologous) protection of neonatal BCG vaccination against hospitalization due to respiratory infection and sepsis","volume":"60","author":"de Castro","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.08.019_b0055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s41479-017-0041-2","article-title":"Risk factors for community-acquired pneumonia among adults in Kenya: a case-control study","volume":"9","author":"Muthumbi","year":"2017","journal-title":"Pneumonia (Nathan)"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.019_b0060","first-page":"695","article-title":"Vaccinations against smallpox and tuberculosis are associated with better long-term survival: a Danish case-cohort study 1971\u20132010","volume":"46","author":"Rieckmann","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"32","key":"10.1016\/j.vaccine.2021.08.019_b0065","doi-asserted-by":"crossref","first-page":"eabc1463","DOI":"10.1126\/sciadv.abc1463","article-title":"Mandated Bacillus Calmette-Gu\u00e9rin (BCG) vaccination predicts flattened curves for the spread of COVID-19","volume":"6","author":"Berg","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2021.08.019_b0070","first-page":"120","article-title":"Further evidence of a possible correlation between the severity of COVID-19 and BCG immunization","volume":"6","author":"Dolgikh","year":"2020","journal-title":"J Infect Dis Epidemiol"},{"issue":"15","key":"10.1016\/j.vaccine.2021.08.019_b0075","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.3390\/ijerph17155589","article-title":"BCG Vaccination and Mortality of COVID-19 across 173 countries: an ecological study","volume":"17","author":"Urashima","year":"2020","journal-title":"Int J Environ Res Public Health"},{"issue":"30","key":"10.1016\/j.vaccine.2021.08.019_b0080","doi-asserted-by":"crossref","first-page":"17720","DOI":"10.1073\/pnas.2008410117","article-title":"BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)","volume":"117","author":"Escobar","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2021.08.019_b0085","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cegh.2020.08.015","article-title":"Is BCG associated with reduced incidence of COVID-19? A meta-regression of global data from 160 countries","volume":"9","author":"Joy","year":"2021","journal-title":"Clin Epidemiol Glob Health"},{"issue":"6","key":"10.1016\/j.vaccine.2021.08.019_b0090","doi-asserted-by":"crossref","first-page":"939","DOI":"10.17269\/s41997-020-00439-7","article-title":"Can BCG be useful to mitigate the COVID-19 pandemic? A Canadian perspective","volume":"111","author":"De Wals","year":"2020","journal-title":"Can J Public Health"},{"issue":"36","key":"10.1016\/j.vaccine.2021.08.019_b0095","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1016\/j.vaccine.2017.06.064","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) vaccination patterns in the province of Qu\u00e9bec, Canada, 1956\u20131974","volume":"35","author":"Rousseau","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.08.019_b0100","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1472-6947-14-2","article-title":"The Qu\u00e9bec BCG Vaccination Registry (1956\u20131992): assessing data quality and linkage with administrative health databases","volume":"14","author":"Rousseau","year":"2014","journal-title":"BMC Med Inform Decis Mak"},{"issue":"6","key":"10.1016\/j.vaccine.2021.08.019_b0105","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1056\/NEJMp2015897","article-title":"False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications","volume":"383","author":"Woloshin","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.08.019_b0110","series-title":"La d\u00e9mographie qu\u00e9b\u00e9coise. Enjeux du XXIe si\u00e8cle [Quebec demography. 21st century challenges]","first-page":"225","article-title":"Un si\u00e8cle d\u2019immigration au Qu\u00e9bec: de la peur \u00e0 l\u2019ouverture [A century of immigration to Quebec: from fear to openness]","author":"Pich\u00e9","year":"2003"},{"key":"10.1016\/j.vaccine.2021.08.019_b0115","unstructured":"Institut National de Sant\u00e9 Publique du Qu\u00e9bec. Indice de d\u00e9favorisation mat\u00e9rielle et sociale. https:\/\/www.inspq.qc.ca\/defavorisation\/indice-de-defavorisation-materielle-et-sociale. Accessed 27 July 2021."},{"issue":"26","key":"10.1016\/j.vaccine.2021.08.019_b0120","doi-asserted-by":"crossref","first-page":"E702","DOI":"10.1503\/cmaj.200869","article-title":"Anosmia and dysgeusia associated with SARS-CoV-2 infection: an age-matched case-control study","volume":"192","author":"Carignan","year":"2020","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2021.08.019_b0125","series-title":"Un r\u00eave, une lutte [One dream, one struggle]","author":"Frappier","year":"1992"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.019_b0130","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1017\/S0003055418000783","article-title":"Using a probabilistic model to assist merging of large-scale administrative records","volume":"113","author":"Enamorado","year":"2019","journal-title":"Am Polit Sci Rev"},{"key":"10.1016\/j.vaccine.2021.08.019_b0135","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020. https:\/\/www.R-project.org\/."},{"issue":"5","key":"10.1016\/j.vaccine.2021.08.019_b0140","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.vaccine.2021.08.019_b0145","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"10269","key":"10.1016\/j.vaccine.2021.08.019_b0150","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.vaccine.2021.08.019_b0155","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1007\/s11606-020-06244-9","article-title":"Expert forecasts of COVID-19 vaccine development timelines","volume":"35","author":"Kane","year":"2020","journal-title":"J Gen Intern Med"},{"issue":"1-2","key":"10.1016\/j.vaccine.2021.08.019_b0160","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cell.2017.12.031","article-title":"BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis","volume":"172","author":"Kaufmann","year":"2018","journal-title":"Cell"},{"issue":"37","key":"10.1016\/j.vaccine.2021.08.019_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17370","article-title":"Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Gu\u00e9rin vaccination against tuberculosis","volume":"17","author":"Abubakar","year":"2013","journal-title":"Health Technol Assess"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.019_b0170","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1586\/14760584.5.2.277","article-title":"Bacillus Calmette-Gu\u00e9rin vaccination and infant mortality","volume":"5","author":"Roth","year":"2006","journal-title":"Expert Rev Vaccines"},{"issue":"22","key":"10.1016\/j.vaccine.2021.08.019_b0175","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.2020.8189","article-title":"SARS-CoV-2 rates in BCG-vaccinated and unvaccinated young adults","volume":"323","author":"Hamiel","year":"2020","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.vaccine.2021.08.019_b0180","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1093\/cid\/ciaa1223","article-title":"BCG vaccination in infancy does not protect against COVID-19. Evidence from a natural experiment in Sweden","volume":"72","author":"de Chaisemartin","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.019_b0185","doi-asserted-by":"crossref","first-page":"e145157","DOI":"10.1172\/JCI145157","article-title":"BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers","volume":"131","author":"Rivas","year":"2021","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.019_b0190","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.jinf.2020.11.022","article-title":"Letter in response to article in journal of infection: impact of routine infant BCG vaccination on COVID-19","volume":"82","author":"Levi","year":"2021","journal-title":"J Infect"},{"issue":"17","key":"10.1016\/j.vaccine.2021.08.019_b0195","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.vaccine.2013.02.053","article-title":"The test-negative design for estimating influenza vaccine effectiveness","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"issue":"37","key":"10.1016\/j.vaccine.2021.08.019_b0200","doi-asserted-by":"crossref","first-page":"20585","DOI":"10.2807\/1560-7917.ES2013.18.37.20585","article-title":"The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials","volume":"18","author":"De Serres","year":"2013","journal-title":"Eurosurveillance"},{"issue":"29","key":"10.1016\/j.vaccine.2021.08.019_b0205","doi-asserted-by":"crossref","first-page":"2100670","DOI":"10.2807\/1560-7917.ES.2021.26.29.2100670","article-title":"Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021","volume":"26","author":"Kissling","year":"2021","journal-title":"Euro Surveill"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.019_b0210","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1056\/NEJMc2104974","article-title":"Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants","volume":"385","author":"Abu-Raddad","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.08.019_b0215","doi-asserted-by":"crossref","DOI":"10.7326\/M21-1577","article-title":"SARS-CoV-2 vaccine effectiveness in a high-risk national population in a real-world setting","author":"Butt","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2021.08.019_b0220","article-title":"Prevention of COVID-19 by mRNA-based vaccines within the general population of California","author":"Andrejko","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2021.08.019_b0225","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.08.019_b0230","article-title":"Single-dose mRNA vaccine effectiveness against SARS-CoV-2, including Alpha and Gamma variants: a test-negative design in adults 70 years and older in British Columbia, Canada","author":"Skowronski","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.08.019_b0235","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01446-y","article-title":"mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar","author":"Chemaitelly","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2021.08.019_b0240","doi-asserted-by":"crossref","first-page":"n1088","DOI":"10.1136\/bmj.n1088","article-title":"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study","volume":"373","author":"Lopez Bernal","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.019_b0245","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ajic.2020.07.011","article-title":"Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19","volume":"49","author":"B\u00f6ger","year":"2021","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.vaccine.2021.08.019_b0250","doi-asserted-by":"crossref","first-page":"104578","DOI":"10.1016\/j.jcv.2020.104578","article-title":"Comparison of the analytical sensitivity of seven commonly used commercial SARS-CoV-2 automated molecular assays","volume":"130","author":"Mostafa","year":"2020","journal-title":"J Clin Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2021.08.019_b0255","first-page":"ofaa399","article-title":"What Is the Predictive Value of a Single Nasopharyngeal SARS-CoV-2 PCR Swab Test in a Patient With COVID-Like Symptoms and\/or Significant COVID-19 Exposure? Open Forum","volume":"7","author":"George","year":"2020","journal-title":"Infectious Diseases"},{"key":"10.1016\/j.vaccine.2021.08.019_b0260","unstructured":"De Serres G, Carazo S, Villeneuve J, Laliberte D, Martin R, Denis G, et al. Enqu\u00eate \u00e9pid\u00e9miologique sur les travailleurs de la sant\u00e9 atteints par la COVID-19 : rapport d\u2019\u00e9tape pour la p\u00e9riode du 12 juillet 2020 au 16 janvier 2021. Institut national de sant\u00e9 publique du Qu\u00e9bec; 2021. https:\/\/www.inspq.qc.ca\/publications\/3137-enquete-epidemiologique-travailleurs-sante-atteints-covid19 Accessed 27 July 2021."},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.019_b0265","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/21645515.2017.1382788","article-title":"The patterns of in vitro cell-death and inflammatory cytokines induced by distinct BCG vaccine strains are differentially induced in human mononuclear cells","volume":"14","author":"Ponte","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.08.019_b0270","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-3-319-64371-7_8","article-title":"Evolution and strain variation in BCG","volume":"1019","author":"Abdallah","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"10.1016\/j.vaccine.2021.08.019_b0275","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/14760584.2018.1483727","article-title":"The influence of BCG on vaccine responses - a systematic review","volume":"17","author":"Zimmermann","year":"2018","journal-title":"Expert Rev Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21010392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21010392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:05:34Z","timestamp":1759403134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21010392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":55,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0264410X21010392"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.019","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does BCG provide long-term protection against SARS-CoV-2 infection? A case\u2013control study in Quebec, Canada","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}